The impact of pharmacogenetics and pharmacogenomics on drug discovery

Nature Reviews Drug Discovery

Volumn 1, Issue 6, 2002, Pages 463-469

  Lindpaintner, Klaus ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ARACHIDONATE 5 LIPOXYGENASE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CELL NUCLEUS DNA; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY; ONCOPROTEIN; RNA 16S; TRASTUZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BREAST CANCER; DIFFERENTIAL DIAGNOSIS; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEGAL ASPECT; MEDICAL ETHICS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL ASPECT; DRUG EFFECT; GENE EXPRESSION; GENOMICS; PALLIATIVE THERAPY;

GENE EXPRESSION; GENOMICS; HUMANS; PALLIATIVE CARE; PHARMACOGENETICS;

EID: 0036596857     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd823     Document Type: Article

References (20)

1. Baselga, J. et al. Phase II study of weekly intravenous recombinant humanized anti-p185 (HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744 (1996).
2. Haseltine, W. A. Not quite pharmacogenomics. Nature Biotechnol. 16, 1295 (1998).
3. In, K. H. et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest. 99, 1130-1137 (1997).
4. McGraw, D. W., Forbes, S. L., Kramer, L. A. & Liggett, S. B. Polymorphisms of the 5′ leader cistron of the human β2-adrenergic receptor regulate receptor expression. J. Clin. Invest 102, 1927-1932 (1998).
5. Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 2, 1240-1243 (1996).
6. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural gene. Science 273, 1856-1862 (1996).
7. Samson, M. et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725 (1996).
8. O'Brien, T. R. et al. HIV-1 infection in a man homozygous for CCR5Δ32. Lancet 349, 1219 (1997).
9. Theodorou, I. et al. HIV-1 infection in an individual homozygous for CCR5Δ32. Lancet 349, 1219-1220 (1997).
10. Drazen, J. M. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168-170 (1999).
11. Martinez, F. D., Graves, P. E., Baldinim M., Solomon, S. & Erickson, R. Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100, 3184-3188 (1997).
12. Tan, S., Hall, I. P., Dewar, J., Dow, E. & Lipworth, B. Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350, 995-999 (1997).
13. Green, S. A., Turki, J., Innis, M. & Liggett, S. B. Amino-terminal polymorphisms of the human β2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33, 9414-9419 (1994).
14. Green, S. A., Turki, J., Bejarano, P., Hall, I. P. & Liggett, S. B. Influence of β2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13, 25-33 (1995).
15. Reihsaus, E., Innis, M., MacIntyre, N. & Liggett, S. B. Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell. Mol. Biol. 8, 334-349 (1993).
16. Dewar, J. C. et al. β2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin. Exp. Allergy 28, 442-448 (1998).
17. Fischel-Ghodsian, N. Genetic factors in aminoglycoside toxicity Ann. NY Acad. Sci. 884, 99-109 (1999).
18. Hutchin, T. & Cortopassi, G. Proposed molecular and cellular mechanism for aminoglycoside ototoxicity. Antimicrob. Agents Chemother. 38, 2517-2520 (1994).
19. Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
20. Roses, A. Pharmacogenetics and future drug development and delivery. Lancet 355, 1358-1361 (2000).